Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479754 | 0.80 | HDAC1 (0.71) | HDAC1HDAC6HTTCYP19A1STS | |
| SCHEMBL5480131 | 0.79 | CYP19A1 (0.61) | MAPTHTTALDH1A1GAAHPGD | |
| SCHEMBL3639750 | 0.79 | HDAC1 (0.73) | HDAC1HDAC6HTTALDH1A1CYP19A1 | |
| SCHEMBL306427 | 0.77 | HDAC1 (0.70) | HDAC1HDAC6HTTCYP19A1STS | |
| SCHEMBL5480229 | 0.75 | BCHE (0.62) | MAPTHTTALDH1A1GAAHPGD | |
| SCHEMBL5481317 | 0.74 | HDAC1 (0.51) | HDAC1HDAC6CYP19A1STSKMT2A | |
| SCHEMBL5477573 | 0.74 | MAPT (0.61) | MAPTHTTALDH1A1GAAHPGD | |
| SCHEMBL12977861 | 0.73 | HDAC1 (0.56) | HDAC1HDAC6HTTGAACYP19A1 | |
| SCHEMBL305312 | 0.73 | CYP19A1 (0.67) | HDAC1HDAC6CYP19A1STS | |
| SCHEMBL5946453 | 0.73 | MAPT (0.77) | MAPTHTTALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | HDAC1 498/4885HDAC6 1059/4885MAPT 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.